Immunitybio Inc (IBRX : NASDAQ)
Common Stock
$9.29
USD
+0.84 (9.94%)
Last updated: 2026-09-22
Get IBRX alerts:
IBRX
Immunitybio Inc
WealthAwesomePerformance
1 Day
+9.94%
1 Week
+14.13%
1 Month
+19.26%
YTD
+32.90%
Key Statistics
Market Cap
$8.96B
52W High
$12.43
52W Low
$1.95
P/E Ratio
-
50 Day MA
$7.75
200 Day MA
$6.90
Beta
0.14
Dividend Yield
-
Advertisement
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 9/22/2026 | $8.45 | $9.48 | $8.37 | $9.29 | $9.29 | 21,006,217 |
| 9/21/2026 | $8.72 | $8.87 | $8.26 | $8.45 | $8.45 | 12,238,176 |
| 9/18/2026 | $8.46 | $8.53 | $8.20 | $8.48 | $8.48 | 18,414,300 |
| 9/17/2026 | $8.14 | $8.80 | $8.12 | $8.46 | $8.46 | 19,099,916 |
| 9/16/2026 | $8.13 | $8.30 | $7.76 | $7.91 | $7.91 | 9,154,936 |
| 9/15/2026 | $8.32 | $8.34 | $7.85 | $8.14 | $8.14 | 8,949,305 |
| 9/14/2026 | $7.89 | $8.40 | $7.87 | $8.37 | $8.37 | 9,158,261 |
| 9/11/2026 | $7.80 | $8.35 | $7.80 | $7.91 | $7.91 | 12,468,768 |
| 9/10/2026 | $7.87 | $7.89 | $7.64 | $7.72 | $7.72 | 8,797,200 |
| 9/9/2026 | $8.22 | $8.36 | $7.88 | $8.06 | $8.06 | 9,485,900 |
Analyst Price Targets
Based on 5 analysts covering IBRX · as of Sep 17, 2026
Wall Street analysts forecast IBRX stock price to rise 37.2% over the next 12 months.
Consensus
Strong Buy4.60 / 5.00
Avg. Target
US$12.75
+37.2% Upside
Current Price
US$9.29
Last close
Analyst Breakdown (5 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IBRX's historical volatility
30-Day Vol
57.9%
Annualized
90-Day Vol
63.7%
Annualized
Trend (90d)
+27.1%
Annualized drift
90d Mean
US$10.23
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$9.59 | US$7.86 – US$11.71 |
| 60 trading days | US$9.91 | US$7.47 – US$13.14 |
| 90 trading days | US$10.23 | US$7.24 – US$14.46 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Immunitybio Inc
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
Financials
- Revenue (TTM)
- $165.79M
- EBITDA
- $-235.30M
- Profit Margin
- 0.00%
- ROE (TTM)
- 0.00%
- EPS (Diluted)
- -0.95
- Book Value
- -0.99
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Advertisement
Common Questions About IBRX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| LHSW | Lianhe Sowell International Group Ltd Ordinary Shares | $0.89 | +105.33% |
| KFIIR | K&F Growth Acquisition Corp. II Rights | $0.09 | +73.36% |
| ZEO | Zeo Energy Corp. | $0.49 | +57.04% |
| RAIN | Rain Enhancement Technologies Holdco, Inc. Class A Common Stock | $1.02 | +54.31% |
| NBRGR | Newbridge Acquisition Limited Rights | $0.36 | +53.19% |
| GRML | Greenland Mines Ltd | $14.15 | +50.21% |
| CWD | CaliberCos Inc. Class A Common Stock | $0.73 | +40.33% |
| FLNA | Filana Therapeutics, Inc. | $1.03 | +39.28% |
IBRX.US news timeline
1 article covering IBRX.US, most recent first
Latest